# Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

> **NCT02442063** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 15 (actual)

## Conditions studied

- Neoplasms
- Bone Diseases

## Interventions

- **DRUG:** Radium Ra 223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02442063
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442063, "Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02442063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*